Patrys Limited (AU:PAB) has released an update.
Patrys Limited has completed a GMP production run of its therapeutic antibody PAT-DX1, with specification testing expected to conclude by July 2024. The company has also presented promising preclinical data suggesting its deoxymabs could be effective in treating vasculitis and other autoimmune diseases. As of June 30, 2024, Patrys reported a cash balance of $2.2 million, with ongoing research and development activities.
For further insights into AU:PAB stock, check out TipRanks’ Stock Analysis page.
